Siemens Healthineers is developing a leading POC product for the rapid detection of acute SARS-COV2 (COVID-19) infection




Product Point Of Care RAPID COVID-19 Antigen test Sample types: Nasal Swab Throat Swab Saliva Time to result = 15-20 mins Easy to use visual read; no instrument required



Specifications


- Double antibody based, lateral flow chromatographic immunoassay
- · Qualitative detection of the SARS-COV2 virus antigen in various sample types include nasal and throat swabs
- . No cross-reactivity detected with MERS, 4 common coronaviruses, Flu A or Flu B
- · Expected sensitivity and specificity: On par or better than existing approved Antigen tests in market
 - Targeted sensitivity > 96.5%
 - Targeted specificity > 99.5%
- Intended for professional use only
- · Future iterations may include pharmacy and/or home use



Restricted © Siemens Healthcare Diagnostics Inc., 2020

SARS-COV-2 Infektion Einordnung von Antigen in den Krankheitsverlauf







Different types of COVID-19 test can detect the presence of the SARS-CoV-2 virus or the body's response to infection. The probability of a positive result varies with each test before and after symptoms appear.

PCR-based tests can detect small amounts of viral genetic material, so a test can be positive long after a person stops being infectious.

- Rapid antigen tests detect the presence of viral proteins and can return positive results when a person is most infectious.


- Antibody tests detect the body's immune response to the virus and are not effective at the earliest phase of infection.

Exposure Symptom to virus onset

CWE DX | CLINITEST Rapid SARS-CoV-2 Restricted © Siemens Healthcare Diagnostics Inc., 2020

Der Einsatz des SARS-COV-2 Antigen Tests unterstützt die Eindämmung und verhindert die Ausbreitung von COVID-19





CWE DX | CLINITEST Rapid SARS-CoV-2 Restricted © Siemens Healthcare Diagnostics Inc., 2020